Palo Alto, CANCT03510208Now EnrollingIRB Ready

Malignant Brain Neoplasm Clinical Trial in Palo Alto, CA

Access cutting-edge malignant brain neoplasm treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.

Sponsored by Stanford University

Quick Self-Assessment

See if you qualify for this Palo Alto location

Preparing your pre-screening questions…

Expert Care in Palo Alto

Access malignant brain neoplasm specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related malignant brain neoplasm treatment provided free

Apply for This Palo Alto Location

Check if you qualify for this malignant brain neoplasm clinical trial in Palo Alto, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Palo Alto

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Palo Alto site if eligible
  4. 4Begin participation

About This Malignant Brain Neoplasm Study in Palo Alto

The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better distinguish tumor cells from normal brain tissue and identify small tumors that cannot be seen using current imaging methods.

Sponsor: Stanford University

Who Can Participate

Inclusion Criteria

1\) One of the following:
Cohorts 1, 2, and 3: Participants with suspected or confirmed diagnosis of glioblastoma
Cohort 4: Participants with suspected or confirmed diagnosis of vestibular schwannoma 2.) Planned surgical removal of the tumor as part of standard of care. This may include participants postchemotherapy, post-radiation, and/or participants who have undergone diagnostic biopsy for their original diagnosis and are felt to be candidates for resection. 3\) Participant age ≥ 18 years. 4\) Participants or their designated advocates must be willing to and capable of providing informed consent and willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

Exclusion Criteria

Received an investigational drug within 30 days prior to first dose of Panitumumab-IRDye800.
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease as determined by PI; or unstable angina within 6 months prior to enrollment.
History of infusion reactions to monoclonal antibody therapies
Pregnant or breastfeeding.
Evidence of QTc prolongation on pretreatment ECG (greater than 440 ms in males or greater than 460 ms in females).
Any of the following lab values:
Platelet count \< 75,000/mm3
TSH ≥ 13 micro International Units/mL.
Magnesium, potassium, or calcium \< each respective upper limit of normal
Serum creatinine \> 1.5 times upper limit of normal
Participants receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
Participants with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.
Participants not deemed by PI to be appropriate candidates for optimal resection of tumor based on location, involvement of eloquent brain, satellite lesions, or other factors not specifically listed here.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Palo Alto?

Yes, this clinical trial (NCT03510208) has an active research site in Palo Alto, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Malignant Brain Neoplasm Treatment Options in Palo Alto, CA

If you're searching for malignant brain neoplasm treatment options in Palo Alto, CA, this clinical trial (NCT03510208) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced malignant brain neoplasm specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all malignant brain neoplasm clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Palo Alto, CA

See all rheumatoid arthritis clinical trials recruiting in Palo Alto — not just this study.

Browse Rheumatoid Arthritis Trials in Palo Alto →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Palo Alto?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Palo Alto, CA